cd1a-car t
Lymphoblastic T-Cell Lymphoma
OneChain ImmunotherapeuticsCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
45 Active assets in the Lymphoblastic T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
METHOTREXATE Children's Oncology Group | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
ASPARAGINASE University of Washington | Phase 3 | BB |
Cyclophosphamide Children's Oncology Group | Phase 3 | BB |
View all 50 →
Same molecule, other indications
cd1a-car t is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →